Phase 1/2 ReSPECT-GBM Trial of Rhenium (186Re) Obisbemeda in Recurrent Glioblastoma: Safety and Efficacy from the Phase 1 and Update on Phase 2 (SNO 2025) - Dec 2, 2025 - Abstract #CTNI-43; Pres time: Nov 21, 2025; 11:30 AM - 12:45 PM; Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III; "Rhenium (186Re) Obisbemeda (186RNL; Reyobiq), a novel radiotherapeutic consisting of 186Re encapsulated in nanoliposomes, is under investigation for convection enhanced delivery in recurrent glioblastoma (GBM) in the Phase 1/2 ReSPECT-GBM trial (IND 116117)...Preliminary efficacy data from Phase 1 cohorts 1 to 6 (N=21) showed a median overall survival (mOS) of 17.0 months (95% CI 8.0–35.0) for patients receiving ≥100 Gy (n=12), compared to 6.0 months (95% CI 1.0–11.0) for those receiving <100 Gy (N=9), surpassing historical bevacizumab monotherapy outcomes (mOS ~7.4–9.2 months)...SPECT/CT imaging confirms high tumor-specific radiation retention, with minimal systemic exposure. These results support Reyobiq's promising safety and efficacy profile, warranting further investigation as a novel therapeutic for recurrent GBM, addressing a critical unmet medical need."
Clinical • P1/2 data • P2 data • Brain Cancer • CNS Disorders • Cognitive Disorders • Developmental Disorders • Glioblastoma • Solid Tumor
|
|
Andrew Brenner; Michael Youssef; Michael Schulder; Pierre Giglio; Joel Michalek; Ande Bao; William Phillips; Melissa Moore; Michael Rosol; Marc Hedrick; William Kelly; John Floyd; Toral Patel
|